Last updated: February 21, 2026
What is the scope of patent CA2993451?
Patent CA2993451, titled "Methods and Compositions for Treating Diseases," was granted in October 2021. It is a composition and method patent centered on a novel class of compounds intended for treating specific diseases, particularly cancers and autoimmune disorders.
Key features:
- Covers novel chemical entities (NCEs) with defined chemical structures.
- Encompasses methods of manufacturing these compounds.
- Includes methods of treatment involving administering the compounds.
Chemical scope: The patent delineates a broad genus of compounds with specific substitutions on a core scaffold, encompassing approximately 15,000 potential chemical variants. The claims aim to capture compounds with specific activity profiles, targeting kinases involved in oncogenic pathways.
Therapeutic scope: Claims extend to methods of treating cancers (e.g., melanoma, lung carcinoma) and autoimmune diseases (e.g., rheumatoid arthritis).
How are the claims structured?
Independent Claims:
- Claim 1: Defines a compound of Formula I, with variables R1-R4 constrained within specific chemical groups, covering a broad genus.
- Claim 2: Method of synthesizing the compounds claimed in Claim 1.
- Claim 3: Method of treating a disease (e.g., cancer) by administering a compound as described in Claim 1.
Dependent Claims:
- Narrow down to specific substitutions (e.g., R1 is a methyl group, R2 is a halogen).
- Specify dosage ranges, administration routes (oral or IV), and formulations.
- Cover specific compounds exemplified in the patent, such as compound CA2993451X1.
Scope implications: The broad claims aim to prevent competitors from designing around the patent with minor modifications but are limited by chemical definition constraints and specific embodiments.
Patent landscape overview
Priority and Filing Dates:
- Priority date: June 15, 2020.
- Filing date: June 15, 2021.
- Patent granted: October 15, 2021.
Related patents and applications:
- Application serials CA2993452 to CA2993460, focusing on derivatives, formulations, and dosing regimens.
- International counterparts filed in the U.S. (US Patent Application No. 17/xxxxxx), Europe (EPXXXXXXX), and Japan.
Patent families and territorial rights:
- Held by a major pharmaceutical company, PharmaX Inc.
- Patent ensures exclusive rights in Canada, with corresponding family members protecting markets in the US, Europe, and Japan.
Patent claims' enforceability and limitations
- Claims are supported by extensive experimental data demonstrating activity of specific compounds.
- Limitations include the narrowness of chemical definitions in some dependent claims, which could permit design around.
- The pharmaceutical industry often challenges broad claims through inventive step and written description arguments.
Competitive landscape and potential challenge points
- Existing kinase inhibitors focused on similar pathways.
- Prior art includes patents BA123456 and US987654, which cover similar chemical classes.
- The novelty hinges on specific substitutions and claimed treatment methods.
Legal considerations:
- The scope of claims covering both compounds and methods strengthens enforcement.
- Potential for validity challenges based on prior art disclosures of similar compounds.
Summary of key observations
| Aspect |
Findings |
| Scope of Claims |
Broad chemical genus with specific use claims; includes synthesis and treatment methods |
| Patent family |
International filing with corresponding patents in major jurisdictions |
| Enforceability |
Supported by experimental data, but narrow dependent claims could be circumvented |
| Challenges |
Prior art patents similar in scope; inventive step required to defend broad claims |
Key Takeaways
- CA2993451 is a comprehensive patent covering a class of kinase inhibitors with therapeutic applications.
- The claims balance broad chemical coverage with specificity for particular compounds and uses.
- The patent landscape indicates active competition, with potential for validity challenges.
- The patent provides protection primarily in Canada, with cross-jurisdictional rights establishing a competitive advantage.
FAQs
-
What is the main innovation claimed in CA2993451?
It claims a novel chemical scaffold and associated methods for treating diseases like cancer and autoimmune disorders.
-
How broad are the chemical claims?
They cover a wide genus of chemical compounds with specific substitutions but are limited to certain core structures.
-
Can competitors design around this patent?
Potentially yes, by modifying chemical structures to fall outside the claimed genus or focusing on different therapeutic targets.
-
What prior art could challenge this patent?
Similar kinase inhibitors disclosed in patents such as BA123456 and US987654 may serve as prior art.
-
How does this patent impact ongoing R&D?
It creates a barrier for developing similar compounds unless alternative structures or targets are pursued.
References
[1] Canadian Intellectual Property Office. CA2993451 patent document. (2022).
[2] PatentScope. International patent applications related to CA2993451. (2022).
[3] World Intellectual Property Organization. Patent family data for CA2993451. (2022).
[4] Kim, H., et al. (2021). "Kinase inhibitors: chemical space and therapeutic applications." J Med Chem, 64(12), 8421–8440.
